MAPT and Alzheimer disease: Finally, in vitro experiments are conducted in Aβ25–35-induced PC12 cells to evaluate MFXD’s effects on cell viability (via CCK-8), the expression of core proteins (p-NF-κB p65, NF-κB p65, p-GSK-3β, GSK-3β, MMP-9, p-Tau, and total Tau) via Western blot, and the secretion of inflammatory factor TNF-α (via ELISA), thereby providing quantitative evidence for MFXD’s therapeutic role in AD and revealing its underlying mechanism.